echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > BMS' CAR-T cell therapy for multiple myeloma has been approved by the FDA

    BMS' CAR-T cell therapy for multiple myeloma has been approved by the FDA

    • Last Update: 2021-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Bristol Myers Squibb (BMS) and Bluebird Bio announced on Friday that the FDA has approved its application for BCMA - targeted CAR-T cell therapy Abecma (idecabtagene vicleucel) to treat relapsed or refractory multiple bone marrow Tumor patients.


    FDA CAR-T

    The therapy is approved as a one-time infusion, and the recommended dose range is 300 to 460 * 10 6 CAR-positive T cells.


    6 Immunity

    The two companies said this approval is supported by data from the key Phase II KarMMa trial, which evaluated the effectiveness and safety of Abecma (idecabtagene vicleucel) in the treatment of relapsed or refractory multiple myeloma (127 patients) .


    The results recently published on NEJM showed that among 100 patients whose efficacy can be evaluated, the overall response rate (ORR) of the Abecma (idecabtagene vicleucel) group was 72%.


     

    Original source:

    Original source:

    href="" target="_blank" rel="noopener">leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.